460,047 Solventum Corporation $SOLV Shares Sold by Boston Partners

Solventum logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Boston Partners cut its Solventum stake by 11.4%, selling 460,047 shares in the third quarter; it still held 3.58 million shares, worth about $315 million.
  • Solventum reported quarterly EPS of $1.45, beating the $1.34 consensus, and revenue of $1.95 billion, above expectations but down 7% year over year.
  • Analyst sentiment remains generally positive: MarketBeat reports a “Moderate Buy” consensus rating and a $90.27 average price target.
  • Interested in Solventum? Here are five stocks we like better.

Boston Partners lessened its holdings in shares of Solventum Corporation (NYSE:SOLV - Free Report) by 11.4% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,577,916 shares of the company's stock after selling 460,047 shares during the quarter. Boston Partners owned 2.11% of Solventum worth $315,383,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the business. Laurel Wealth Advisors LLC bought a new position in shares of Solventum in the third quarter valued at $29,000. JNBA Financial Advisors increased its position in shares of Solventum by 71.9% during the second quarter. JNBA Financial Advisors now owns 507 shares of the company's stock worth $39,000 after acquiring an additional 212 shares in the last quarter. Ameritas Advisory Services LLC bought a new stake in shares of Solventum during the second quarter worth about $47,000. Ancora Advisors LLC bought a new stake in shares of Solventum during the second quarter worth about $56,000. Finally, Root Financial Partners LLC acquired a new stake in shares of Solventum in the 3rd quarter worth about $68,000.

Analyst Ratings Changes

Several brokerages recently weighed in on SOLV. Benchmark reaffirmed a "buy" rating on shares of Solventum in a research report on Thursday, October 8th. UBS Group boosted their price objective on Solventum from $95.00 to $101.00 and gave the stock a "buy" rating in a report on Thursday, August 6th. Weiss Ratings lowered Solventum from a "buy (b-)" rating to a "hold (c-)" rating in a report on Monday, November 9th. Mizuho set a $113.00 price objective on Solventum in a research note on Thursday, August 6th. Finally, Wall Street Zen lowered Solventum from a "buy" rating to a "hold" rating in a report on Saturday, November 7th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Solventum currently has a consensus rating of "Moderate Buy" and a consensus target price of $90.27.

Get Our Latest Research Report on Solventum

Solventum Stock Up 0.4%

Solventum stock opened at $86.43 on Thursday. Solventum Corporation has a fifty-two week low of $62.38 and a fifty-two week high of $94.16. The stock has a market cap of $14.67 billion, a PE ratio of 12.21, a price-to-earnings-growth ratio of 1.22 and a beta of 0.69. The firm's 50-day simple moving average is $87.32 and its 200 day simple moving average is $79.11. The company has a debt-to-equity ratio of 0.99, a quick ratio of 0.72 and a current ratio of 1.03.

Solventum (NYSE:SOLV - Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The company reported $1.45 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.34 by $0.11. The business had revenue of $1.95 billion during the quarter, compared to the consensus estimate of $1.93 billion. Solventum had a net margin of 1.91% and a return on equity of 25.03%. The firm's quarterly revenue was down 7.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.50 EPS. Research analysts predict that Solventum Corporation will post 7.26 EPS for the current fiscal year.

Solventum Company Profile

(Free Report)

Solventum is a global healthcare company that develops products and services for hospitals, dental professionals, health systems and other care providers. It was formed from 3M's healthcare business and became an independent public company in April 2024. The company's offerings include medical and surgical supplies, wound-care products, sterilization and infection-prevention solutions, dental materials and technologies, and software for health information management. Its products and services support clinical care, dental care and healthcare administration.

Featured Articles

Want to see what other hedge funds are holding SOLV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Solventum Corporation (NYSE:SOLV - Free Report).

Institutional Ownership by Quarter for Solventum (NYSE:SOLV)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Solventum Right Now?

Before you consider Solventum, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Solventum wasn't on the list.

While Solventum currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines